Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 80

1.

One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial.

Joensuu H, Eriksson M, Sundby Hall K, Hartmann JT, Pink D, Schütte J, Ramadori G, Hohenberger P, Duyster J, Al-Batran SE, Schlemmer M, Bauer S, Wardelmann E, Sarlomo-Rikala M, Nilsson B, Sihto H, Monge OR, Bono P, Kallio R, Vehtari A, Leinonen M, Alvegård T, Reichardt P.

JAMA. 2012 Mar 28;307(12):1265-72. doi: 10.1001/jama.2012.347.

PMID:
22453568
2.

Gastrointestinal stromal tumors: who should get imatinib and for how long?

Balachandran VP, DeMatteo RP.

Adv Surg. 2014;48:165-83. Review.

3.

Management of localized gastrointestinal stromal tumors and adjuvant therapy with imatinib.

López RL, del Muro XG.

Anticancer Drugs. 2012 Jun;23 Suppl:S3-6. doi: 10.1097/CAD.0b013e3283559fab. Review.

PMID:
22739667
4.

Imatinib: as adjuvant therapy for gastrointestinal stromal tumour.

Sanford M, Scott LJ.

Drugs. 2010 Oct 22;70(15):1963-72. doi: 10.2165/11205000-000000000-00000. Review.

PMID:
20883053
5.

[GIST: adjuvant treatment in Austria].

Brodowicz T, Kühr T.

Wien Med Wochenschr. 2009;159(15-16):399-402. doi: 10.1007/s10354-009-0687-3. Review. German.

PMID:
19696984
6.

Imatinib rechallenge in patients with advanced gastrointestinal stromal tumors.

Blay JY, Pérol D, Le Cesne A.

Ann Oncol. 2012 Jul;23(7):1659-65. doi: 10.1093/annonc/mdr622. Epub 2012 Feb 21. Review.

PMID:
22357253
7.

Optimizing tyrosine kinase inhibitor therapy in gastrointestinal stromal tumors: exploring the benefits of continuous kinase suppression.

Le Cesne A, Blay JY, Reichardt P, Joensuu H.

Oncologist. 2013;18(11):1192-9. doi: 10.1634/theoncologist.2012-0361. Epub 2013 Oct 17. Review.

8.

[Translational research and diagnosis in GIST].

Wardelmann E.

Pathologe. 2012 Nov;33 Suppl 2:273-7. doi: 10.1007/s00292-012-1682-9. Review. German.

PMID:
22968735
9.

[Gastrointestinal stromal tumour (GIST): current standards in multimodal management].

Reichardt P, Reichardt A.

Zentralbl Chir. 2011 Aug;136(4):359-63. doi: 10.1055/s-0031-1271596. Epub 2011 Aug 23. Review. German.

PMID:
21863513
10.
11.

[Indications for pre- and postoperative treatment with imatinib for gastrointestinal stromal tumors].

Heger U, Weitz J, Lordick F.

Chirurg. 2008 Jul;79(7):630-7. doi: 10.1007/s00104-008-1526-6. Review. German.

PMID:
18548219
12.

Adjuvant therapy of gastrointestinal stromal tumors (GIST).

Casali PG, Fumagalli E, Gronchi A.

Curr Treat Options Oncol. 2012 Sep;13(3):277-84. doi: 10.1007/s11864-012-0198-0. Review.

PMID:
22743760
13.

Imatinib as adjuvant treatment following resection of KIT-positive gastrointestinal stromal tumours.

Dretzke J, Round J, Connock M, Tubeuf S, Pennant M, Fry-Smith A, Hulme C, McCabe C, Meads C.

Health Technol Assess. 2010 Oct;14(Suppl. 2):63-70. doi: 10.3310/hta14suppl2/09. Review.

14.

Gastrointestinal stromal tumor and its targeted therapeutics.

Dupart J, Zhang W, Trent JC.

Chin J Cancer. 2011 May;30(5):303-14. Review.

15.

Current and emerging pharmacological treatments for gastrointestinal stromal tumour.

Ganjoo KN, Patel S.

Drugs. 2011 Feb 12;71(3):321-30. doi: 10.2165/11585370-000000000-00000. Review.

PMID:
21319869
16.

Molecular basis for primary and secondary tyrosine kinase inhibitor resistance in gastrointestinal stromal tumor.

Gounder MM, Maki RG.

Cancer Chemother Pharmacol. 2011 Jan;67 Suppl 1:S25-43. doi: 10.1007/s00280-010-1526-3. Epub 2010 Nov 30. Review.

17.

Imatinib as adjuvant therapy for gastrointestinal stromal tumors: a systematic review.

Essat M, Cooper K.

Int J Cancer. 2011 May 1;128(9):2202-14. doi: 10.1002/ijc.25827. Review.

18.

Knowns and Known Unknowns of Gastrointestinal Stromal Tumor Adjuvant Therapy.

Martínez-Marín V, Maki RG.

Gastroenterol Clin North Am. 2016 Sep;45(3):477-86. doi: 10.1016/j.gtc.2016.04.006. Review.

PMID:
27546844
19.

Management of gastrointestinal stromal tumors: looking beyond the knife. An update on the role of adjuvant and neoadjuvant imatinib therapy.

Pandey R, Kochar R.

J Gastrointest Cancer. 2012 Dec;43(4):547-52. doi: 10.1007/s12029-012-9423-0. Review.

PMID:
22847491
20.

New fronts in the adjuvant treatment of GIST.

Reichardt P, Joensuu H, Blay JY.

Cancer Chemother Pharmacol. 2013 Oct;72(4):715-23. doi: 10.1007/s00280-013-2248-0. Epub 2013 Aug 11. Review.

PMID:
23934322

Supplemental Content

Support Center